shanghai denovo officially launches phase i clinical study of a new tlr8 agonist dn1508052-亚博88体育

on september 10, shanghai denovo pharmaceuticaltechnology co., ltd., a subsidiary of qingfeng pharmaceutical group, held atlr8 agonist dn1508052-01 phase i clinical trial kick-off meeting at shanghaidongfang hospital, officially launching the project's phase i clinical study.